TOKENPOST
1 min read
Add as a preferred source on Google

Gyre Therapeutics Posts $32.9 Million in Q3 Revenue, $0.04 GAAP Loss Per Share

Revenue rose 0.6% year over year, and the company maintained its 2026 revenue guidance at $100.5 million to $111 million.

By John Kim
Published
Ceramic bars show a slight rise beside a level column / TokenPost.ai
Ceramic bars show a slight rise beside a level column / TokenPost.ai

Gyre Therapeutics, Inc. posted $32.9 million in third-quarter revenue, up 0.6% from a year earlier, and recorded a GAAP loss per share of $0.04.

The company maintained its 2026 revenue guidance at $100.5 million to $111 million.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…